| Title： | Expert consensus on off-label use of HER-2 antibody-drug conjugate |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Administration |
| Countries and regions： | China |
| Guidelines users： | Clinical physicians at all levels (including doctor, pharmacist and other relevant fields) |
| Evidence classification method： | For guidelines and consensus evidence, the evidence category and recommendation level use the grading standards adopted by the original guidelines. Guidelines without marked evidence category and recommendation level and clinical trials are evaluated according to the CSCO evidence grading standards. |
| Development unit： | Zhejiang Cancer Hospital |
| Registration time: | 2024-10-14 |
| Registration number： | PREPARE-2024CN814 |
| Purpose of the guideline: | In recent years, antibody-drug conjugates (ADC) have gradually become one of the hottest research fields related to cancer treatment. Among the approved ADCs, HER-2 is the most explored target. However, the off-label use of anti-HER-2 ADC is common. Based on drug labels, guidelines, expert consensus and published literature evidence, this consensus systematically sorts out and conducts evidence-based evaluation of the off-label use of anti-HER-2 ADC. And the consensus expert group forms recommendations for the off-label use of anti-HER-2 ADC in order to providing reference for the clinical rational use of anti-HER-2 ADC. |
Latest registration
